Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Nov 10 - Nov 15
Credit where it's due: this piece leans on the 2026 creatine + GLP-1 perspective from Darren Candow, Scott Forbes, and Chad Kerksick, and on the muscle-protein-synthesis work of Nicholas Burd and Stuart Phillips
Pathophysiologic and therapeutic implications
Specifically, it boosts dopamine and norepinephrine
Topline data from the Phase 3, open-label EMBER-3 clinical trial among patients with estrogen receptor 1 (ESR1) gene mutations who received prior endocrine therapy revealed a median progression-free survival (PFS) of 5.5 months with imlunestrant compared to 3.8 months with placebo (hazard ratio [HR], 0.62
US$ 29.61
US$ 21.23
US$ 24.75
US$ 20.14
